Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J-SONIC
jRCTs071180049Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) and idiopathic pulmonary fibrosis (IPF) comparing carboplatin + nab-paclitaxel with carboplatin + nab-paclitaxel + nintedanib (2 arms). Primary endpoint: Exacerbation-free survival of idiopathic pulmonary fibrosis. Started May 2017; status: completed.
02
Drugs
carboplatinpaclitaxelnintedanib
03
Conditions
non-small cell lung cancer (NSCLC)idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on jRCTs071180049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180049.